Previous Close | 9.84 |
Open | 9.84 |
Bid | 9.64 x 100 |
Ask | 9.78 x 100 |
Day's Range | 9.67 - 10.00 |
52 Week Range | 4.32 - 15.12 |
Volume | |
Avg. Volume | 146,793 |
Market Cap | 246.497M |
Beta (5Y Monthly) | 0.53 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The transaction, which took place on December 31, 2023, involved the acquisition of 75,537 shares at a trade price of $8.14 per share. This strategic move has expanded Viking Global's holding to a total of 2,531,829 shares in Verastem Inc, reflecting the firm's confidence in the company's future prospects.
On February 6, 2024, Robert Gagnon, a director at Verastem Inc, executed a sale of 9,204 shares of the company.
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.